NAT2 and colorectal cancer: By mining the human genome for common SNVs affecting the functional domains of enzymes, we previously identified the loss of NAT2 as a therapeutic target for colorectal cancer, specifically in cases where the remaining NAT2 allele following LOH has reduced enzymatic activity.3